Publications & presentations
Sumitomo Pharma Oncology conducts extensive scientific and clinical research to support its diverse pipeline. Learn more about ongoing initiatives from the publications, abstracts, and presentations below.
Publications
Sort by:
Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models
Leukemia
2022 ASH Annual Meeting
Preliminary Data From the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients With Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy
Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)–Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)
Activin-like Kinase 2 (ALK2/ACVR1) is a Resistance Factor and Therapeutic Vulnerability to FLT3 Inhibition in Acute Myeloid Leukemia
ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes
2022 ENA Symposium
The PKM2 activator and molecular glue TP-1454 modulates tumor-immune responses by destabilizing T-regulatory cells
The AXL inhibitor, TP-0903, reverses EMT and shows activity in non-small cell lung cancer preclinical models
2022 SOHO Annual Meeting
Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients With Acute Leukemia With and Without Mixed-Lineage Leukemia (MLL)–Rearrangement (r) or Nucleophosmin 1 (NPM1) Mutation (m)
Real-World Ruxolitinib Treatment Pattern in Myelofibrosis Patients With Thrombocytopenia
2022 ASCO Annual Meeting
Phase 1/2, open-label, dose-escalation, dose-expansion study of menin inhibitor DSP-5336 in adult patients with acute leukemia with and without mixed-lineage leukemia (MLL)–rearrangement (r) or nucleophosmin 1 (NPM1) mutation (m)
DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: a first-in-human, phase 1 study
Molecular glues: enhanced protein-protein interactions and cell proteome editing
Medicinal Chemistry Research
2021 AACR Virtual Annual Meeting
PKM2 activation modulates the tumor-immune microenvironment and enhances response to checkpoint inhibitors in preclinical solid tumor models
Pharmacodynamic biomarkers for Pim inhibition with TP-3654 in patients with solid tumors
TP-5809, a novel TNK1 inhibitor, suppresses TNK1 dependent signaling and tumor growth in a preclinical model of Hodgkin’s lymphoma
2020 ESMO Virtual Congress
Phase 1, first-in-human, safety, pharmacokinetic and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumors
2020 ASCO Virtual Scientific Program
A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors
A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 Days to patients with advanced solid tumors
PIM1 (Moloney murine leukemia provirus integration site) inhibition decreases the nonhomologous end-joining DNA damage repair signaling pathway in pulmonary hypertension
Arteriosclerosis, Thrombosis, and Vascular Biology
2019 SITC Annual Meeting, National Harbor, MD
A first-in-human, phase 1, multicenter trial of toll-like receptor (TLR) 7 agonist DSP-0509 as monotherapy and in combination with pembrolizumab in adult patients with advanced solid tumors
TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells
Scientific Reports
Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy
Oncotarget
TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy
European Journal of Pharmacology
Join us
Bring your passion for making a meaningful difference and join our global team to fight cancer with cutting-edge science.
Careers